AbbVie Expands Manufacturing Presence in Singapore - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AbbVie Expands Manufacturing Presence in Singapore


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 3
AbbVie reported a $320 million investment to establish operations in Singapore for small molecule and biologics active drug-substance manufacturing. The completed facility will provide manufacturing capacity for emerging compounds within AbbVie’s oncology and immunology pipeline.

The investment will establish the first manufacturing presence in Asia by AbbVie. Other AbbVie operations in Asia include R&D functions in Tokyo, Japan and Shanghai, China, as well as commercial operations throughout the region. AbbVie’s existing presence in Singapore includes 120 employees, supporting commercial operations, global R&D, and general operations.

The investment is expected to result in more than 250 new employees. The new facility is expected to be fully operational by 2019.

Source: AbbVie

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here